Vision Point Advisory Group, LLC Incyte Corp Transaction History

Vision Point Advisory Group, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 01, 2024	BUY	$51.18 - $63.75 $1,688 - $2,103	33 Added 7.66%	464 $28,000
Q1 2024 May 10, 2024	SELL	$56.55 - $66.59 $1,639 - $1,931	-29 Reduced 6.3%	431 $24,000
Q4 2023 Feb 07, 2024	BUY	$52.16 - $64.19 $3,599 - $4,429	69 Added 17.65%	460 $28,000
Q3 2023 Dec 06, 2023	BUY	$57.77 - $65.93 $11,842 - $13,515	205 Added 110.22%	391 $22,000
Q2 2023 Aug 21, 2023	BUY	$60.95 - $75.51 $11,336 - $14,044	186 New	186 $11,000

706

189M

909K

489K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Vision Point Advisory Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Vision Point Advisory Group, LLC with notifications on news.